R H Ansari
Overview
Explore the profile of R H Ansari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seidman A, Brufsky A, Ansari R, Hart L, Stein R, Schwartzberg L, et al.
Ann Oncol
. 2010 Nov;
22(5):1094-1101.
PMID: 21084429
Background: Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G)...
2.
Mauer A, Kraut E, Krauss S, Ansari R, Kasza K, Szeto L, et al.
Ann Oncol
. 2005 May;
16(8):1320-5.
PMID: 15919687
Background: The aim of the study was to evaluate the efficacy and tolerability of the combination of oxaliplatin, fluorouracil and leucovorin in patients with advanced esophagus cancer. Patients And Methods:...
3.
Eng C, Kindler H, Nattam S, Ansari R, Kasza K, Wade-Oliver K, et al.
Ann Oncol
. 2004 May;
15(6):928-32.
PMID: 15151950
Background: The epothilone B analog, BMS-247550, is a non-taxane microtubulin-stabilizing agent with preclinical activity in taxane-resistant cell lines and phase I activity in colorectal cancer. We conducted a phase II...
4.
Mauer A, Ansari R, Hoffman P, Krauss S, Taber D, Tembe S, et al.
Ann Oncol
. 2003 Apr;
14(5):722-8.
PMID: 12702526
Background: The aim of this study was to evaluate feasibility and tolerability of the three-drug combination of paclitaxel, ifosfamide and carboplatin (TIC) in patients with advanced non-small-cell lung cancer. The...
5.
Sweeney C, Monaco F, Jung S, Wasielewski M, Picus J, Ansari R, et al.
Ann Oncol
. 2002 May;
13(3):435-40.
PMID: 11996476
Background: The purpose was to evaluate the combined anti-microtubular regimen of vinorelbine and estramustine phosphate (EMP) in hormone refractory prostate cancer. Patients And Methods: Weekly vinorelbine 20 mg/m2 (or 15...
6.
Ryan C, Shulman K, Richards J, Kugler J, Sosman J, Ansari R, et al.
Invest New Drugs
. 2000 Jun;
18(2):187-91.
PMID: 10857996
Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. Methods: 13...
7.
Mani S, Schiano T, Garcia J, Ansari R, SAMUELS B, Sciortino D, et al.
Invest New Drugs
. 1999 Jun;
16(3):279-83.
PMID: 10360610
Unlabelled: Although UFT 300 mg/m2/day and leucovorin 90 mg/day administered orally in divided doses administered every 8 hours for 28 days repeated every 35 days could be administered safely to...
8.
Mani S, Kugler J, Knost J, Sciortino D, Gibbons J, Garcia J, et al.
Invest New Drugs
. 1999 Jun;
16(3):275-8.
PMID: 10360609
Metastatic colorectal cancer is very common in the Western hemisphere and current treatment modalities are not effective. In this study a prolonged (150-minute) infusion of gemcitabine at a constant dose...
9.
Vokes E, Ansari R, Masters G, Hoffman P, Klepsch A, Ratain M, et al.
Ann Oncol
. 1998 Dec;
9(10):1085-90.
PMID: 9834820
Background: 9-Aminocamptothecin (9-AC) is a synthetic analogue of camptothecin. Phase I studies, identified the maximum tolerated dose as 1416 micrograms/m2/day x 3 as continuous intravenous infusion (CVI) with dose-limiting neutropenia....
10.
Mani S, Kugler J, Sciortino D, Garcia J, Ansari R, Humerickhouse R, et al.
Ann Oncol
. 1998 Nov;
9(9):1035-7.
PMID: 9818081
Background/objectives: Uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) has broad anti-tumor activity for cancers arising from the gastrointestinal tract. However, there are no...